Anti-CD3 Treatments Move to Phase III Trials

Anti-CD3 treatments have moved into Phase III clinical trials and show promise to delay the progression of diabetes in the newly diagnosed. These achievements demonstrate the success of JDRF’s strategy to fill gaps in the drug development pipeline, by initially funding proof-of-concept clinical trials and then helping small companies move discovery research through early clinical testing until bigger companies step in and fund the large trials needed for FDA approval.

Treatments for Newly Diagnosed Move to Phase III Trials

Anti-CD3 treatments have moved into Phase III clinical trials and show promise to delay the progression of diabetes in the newly diagnosed. These achievements demonstrate the success of JDRF’s strategy to fill gaps in the drug development pipeline, by initially funding proof-of-concept clinical trials and then helping small companies move discovery research through early clinical testing until bigger companies step in and fund the large trials needed for FDA approval.

New NIH Prevention Trial Targets Very High-Risk Relatives

To better understand the development of type 1 diabetes and to evaluate preventive interventions, researchers have initiated clinical studies in the relatives of individuals affected by the disease. A new clinical trial through TrialNet, a multi-center consortium sponsored by the National Institutes of Health, will be testing a drug’s efficacy in stopping the progression of […]